Announcements
- Nanobiotix participera à des conférences investisseurs en mars
- Nanobiotix to Present at Upcoming Investor Conferences in March
- Voting Rights and Shares Capital of the Company
- INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
- Nanobiotix participera à la 6ème conférence annuelle de Biotechnologie de Guggenheim
- Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
- Nanobiotix annonce l’atteinte des conditions pour un paiement d'étape de développement de 20 M$ lié à l'étude mondiale de phase 3 en cours sur le cancer de la tête et du cou
- Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
- INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
- Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
More ▼
Key statistics
As of last trade, Nanobiotix SA (5NRA:STU) traded at 5.45, 218.71% above the 52 week low of 1.71 set on May 04, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.45 |
---|---|
High | 5.60 |
Low | 5.45 |
Bid | 5.15 |
Offer | 6.30 |
Previous close | 5.50 |
Average volume | 0.00 |
---|---|
Shares outstanding | 47.13m |
Free float | 33.48m |
P/E (TTM) | -- |
Market cap | 294.53m USD |
EPS (TTM) | -1.82 USD |
Data delayed at least 15 minutes, as of Mar 27 2024.
More ▼